It’s a nice win for Merck. It will provide a nice floor for the stock going forward, and for all drug stocks, which will provide a nice lift to the overall market.

Everyone’s question now is how much more upside there is in Apple’s products. There’s some pretty hard profit-taking. A lot of longs have gotten nervous.

Oil, oil, oil, the price of oil fell back below $US60 a barrel after some bearish inventory numbers. That was the catalyst that spurred some buying in the stocks.

The Intel revenue warning provided further evidence of slowing growth in corporate earnings. Given that the market has already priced in this slow growth. downside from here should be pretty well muted for U.S. equities.

This may catapult the market higher, especially given the cheap valuations.

The real concern here is ‘stagflation’ possibilities as slowing economic growth combines with higher inflation.

Given the drop in bond yields, stocks which were comparatively cheap before, have become even more attractive to buy. This drop in bond yields may finally be the catalyst we need to propel stocks out...

It’s a nice win for Merck, … It will provide a nice floor for the stock going forward, and for all drug stocks, which will provide a nice lift to the overall market.

Today’s sell-off is simply profit taking and valuation realignment,